Data completeness
1/8 — Limited
SOY-DOME (hexachlorophene) by R-Pharm US. Approved for staphylococcal infections, hiv infections.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOY-DOME is a topical emulsion formulation of hexachlorophene indicated for staphylococcal and HIV infections. The mechanism of action and pharmacologic class are not currently documented in available data. This pre-launch NDA product is sponsored by R-Pharm US.
Pre-Launch
Early-stage product with no established market presence; team scaling will depend on regulatory approval and launch strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on SOY-DOME at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.